Immunotherapy
Conference Coverage
Bullous disorders linked to frequent interruption of immune checkpoint inhibitor treatment
MILAN – It’s not clear why patients receiving cancer immunotherapy treatment develop bullous pemphigoid.
Conference Coverage
Novel immune checkpoint holds ‘great promise’ as melanoma treatment target
MILAN – A monoclonal antibody directed against DC-HIL reduced melanoma growth and metastasis in animal models.
Conference Coverage
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomas
Development plans for anti-CD19, anti-CD20 therapy include phase 2 studies in mantle cell, CD19 CAR T cell relapsers.
Conference Coverage
Checkpoint inhibitor–induced rheumatic complications have unique features
MADRID – The phenotypic musculoskeletal complications of checkpoint inhibitors do not resemble other joint pathology.
Conference Coverage
Skin plus GI adverse events with checkpoint inhibitors linked to risk of additional adverse events
MILAN – Toxicities occurred early in treatment, and having both increased risk of adverse events in other organ systems.
Conference Coverage
EULAR issues guidelines on managing rheumatic complications of cancer immunotherapies
The new guidelines are tailored for rheumatologists, and address diagnosis and treatment.
Conference Coverage
Adjuvant immunotherapy results ‘encouraging’ in early NSCLC
CHICAGO – About one-fifth of patients with resectable non–small cell lung cancer had major pathological responses with atezolizumab monotherapy...
From the Journals
Checkpoint inhibitor rechallenge is possible for select patients
Rechallenge resulted in the recurrence of a grade 2 or higher immune-related adverse event (irAE) in 55% of rechallenged patients, but no deaths...
Conference Coverage
Low intensity bridging may be best path to CAR T in adult ALL
CHICAGO – Researchers examined the use of high- and low-intensity chemotherapy bridging for patients waiting for treatment with a CD19-directed...
From the Journals
Novel anti-PD-1 antibody can be given subcutaneously
“Subcutaneous administration of an anti-PD-1 antibody in patients with advanced solid tumors appears to be feasible,” the investigators wrote.